5.1 The Secretary of State and the Welsh Government Minister for Health and Social Services have issued directions to the NHS in England and Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends use of a drug or treatment, or other technology, the NHS must usually provide funding and resources for it within 3 months of the guidance being published. If the Department of Health issues a variation to the 3-month funding direction, details will be available on the NICE website. When there is no NICE technology appraisal guidance on a drug, treatment or other technology, decisions on funding should be made locally.
5.2 The Department of Health and the manufacturer have agreed that mifamurtide will be available to the NHS with a patient access scheme which makes mifamurtide available at a reduced cost to the NHS. The size of the discount is commercial in confidence. It is the responsibility of the manufacturer to communicate details of the discount to the relevant NHS organisations. Any enquiries from NHS organisations about the patient access scheme should be directed to the manufacturer at the following e-mail address: firstname.lastname@example.org.
5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraph above. This means that, if a patient has osteosarcoma and the doctor responsible for their care thinks that mifamurtide is the right treatment, it should be available for use, in line with NICE's recommendations.
5.4 NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on our website (www.nice.org.uk/guidance/TA235).
Costing template and report to estimate the national and local savings and costs associated with implementation.